3 Growing Immunotherapy Companies: Celldex, Merck, OncoSec
By now, almost all health care-focused investors have heard the term “immunotherapy.” Immunotherapy refers to the treatment of disease by inducing, enhancing, or suppressing an immune response. Companies using immunotherapy to treat cancer are attempting to stimulate one’s immune system in order to reject and eliminate cancerous cells and tumors.
Immunotherapy has actually been around for decades but is just finally starting to come into the spotlight, as companies now have the means and the resources necessary to elevate the science to a new level. Three companies that are especially primed for advancing medicine over the next couple of years include Celldex Therapeutics (NASDAQ:CLDX), Merck (NYSE:MRK), and OncoSec Medical (ONCS.PK).
Celldex Therapeutics has certainly become one of the darlings of the biotechnology industry as shares have increased by roughly 250 percent over the past 52 weeks. Several prominent institutions such as FMR LLC, Franklin Resources, Vanguard, Blackrock, and State Street have taken large stakes in the company on hopes that the company’s immunotherapy platform can advance cancer treatment to a place nobody thought possible just a few years ago.